Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 9, 2013, Pages 1374-1380

  Brunner, Andrew M ^a   Kim, Haesook T ^b   Coughlin, Erin ^a   Alyea, Edwin P ^b   Armand, Philippe ^b   Ballen, Karen K ^a   Cutler, Corey ^b   Dey, Bimalangshu R ^a   Glotzbecker, Brett ^b   Koreth, John ^b   McAfee, Steven L ^a   Spitzer, Thomas R ^a   Soiffer, Robert J ^b   Antin, Joseph H ^b   Ho, Vincent T ^b   Chen, Yi Bin ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Aged; Allogeneic transplantation; Graft versus host disease; Mortality; Relapse

Indexed keywords

BUSULFAN; CALCINEURIN INHIBITOR; CLOFARABINE; FLUDARABINE; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; AGED; AGING; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHIMERA; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE NEOPLASM; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; RISK; SCORING SYSTEM; SURVIVOR; AGE; ALLOTRANSPLANTATION; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

AGE FACTORS; AGED; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84882750971     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.06.008     Document Type: Article

References (34)

1. Artz A.S. From biology to clinical practice: aging and hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012, 18:S40-S45.
2. Appelbaum F.R., Gundacker H., Head D.R., et al. Age and acute myeloid leukemia. Blood 2006, 107:3481-3485.
3. Klingemann H.G., Storb R., Fefer A., et al. Bone marrow transplantation in patients aged 45 years and older. Blood 1986, 67:770-776.
4. Ringdén O.H.M. Outcome after allogeneic bone marrow transplant for leukemia in older adults. JAMA 1993, 270:57-60.
5. Cahn J.Y., Labopin M., Schattenberg A., et al. Allogeneic bone marrow transplantation for acute leukemia in patients over the age of 40 years. Acute Leukemia Working Party of the European Group for Bone Marrow Transplantation (EBMT). Leukemia 1997, 11:416-419.
6. Devine S.M., Hoffman R., Verma A., et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood 2002, 99:2255-2258.
7. Bertz H., Potthoff K., Finke J. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. JClin Oncol 2003, 21:1480-1484.
8. Lim Z., Brand R., Martino R., et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. JClin Oncol 2010, 28:405-411.
9. Estey E., De Lima M., Tibes R., et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 2007, 109:1395-1400.
10. Kröger N. Allogeneic stem cell transplantation for elderly patients with myelodysplastic syndrome. Blood 2012, 119:5632-5639.
11. McClune B.L., Weisdorf D.J., Pedersen T.L., et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. JClin Oncol 2010, 28:1878-1887.
12. Koreth J., Aldridge J., Kim H.T., et al. Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age. Biol Blood Marrow Transplant 2010, 16:792-800.
13. Ho V.T., Aldridge J., Kim H.T., et al. Comparison of tacrolimus and sirolimus (Tac/Sir) versus tacrolimus, sirolimus, and mini-methotrexate (Tac/Sir/Mtx) as acute GVHD prophylaxis after reduced intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2009, 15:844-850.
14. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106:2912-2919.
15. Armand P., Gibson C.J., Cutler C., et al. Adisease risk index for patients undergoing allogeneic stem cell transplantation. Blood 2012, 120:905-913.
16. Grimwade D., Hills R.K., Moorman A.V., et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010, 116:354-365.
17. Bacigalupo A., Ballen K., Rizzo D., et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009, 15:1628-1633.
18. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
19. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant 2005, 11:945-956.
20. Vigorito A.C., Campregher P.V., Storer B.E., et al. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood 2009, 114:702-708.
21. Gray R.J. Aclass of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988, 16:1141-1154.
22. Fine J.P., Gray R.J. Aproportional hazards model for the subdistribution of a competing risk. JAm Stat Assoc 1999, 94:496-509.
23. Sorror M.L., Logan B.R., Zhu X., et al. Prospective validation of the predictive power of the hematopoietic cell transplantation comorbidity index (HCT-CI) for HCT outcomes at US transplant centers: a Center for International Blood and Marrow Transplant Research (CIBMTR) Study. Blood 2012, 120(21):733.
24. Chen Y.-B., Coughlin E., Kennedy K.F., et al. Busulfan dose intensity and outcomes in reduced intensity allogeneic peripheral blood stem cell transplantation for MDS/AML. Biol Blood Marrow Transplant 2013, 19(60):981-987.
25. Platzbecker U., Schetelig J., Finke J., et al. Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine. Biol Blood and Marrow Transplant 2012, 18:1415-1421.
26. Murphy W.J., Artz A.S., Champlin R.E., et al. Blood stem cell transplantation in older patients. Biol Blood Marrow Transplant 2009, 15:1638-1639.
27. Appelbaum F.R. What is the impact of hematopoietic cell transplantation (HCT) for older adults with acute myeloid leukemia (AML)?. Best Pract Res Clin Haematol 2008, 21:667-675.
28. Chevallier P., Szydlo R.M., Blaise D., et al. Reduced-intensity conditioning before allogeneic hematopoietic stem cell transplantation in patients over 60 years: a report from the SFGM-TC. Biol Blood Marrow Transplant 2012, 18:289-294.
29. Sorror M.L., Sandmaier B.M., Storer B.E., et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA 2011, 306:1874-1883.
30. Mohty M., de Lavallade H., Ladaique P., et al. The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor versus no donor comparison. Leukemia 2005, 19:916-920.
31. Abel G.A., Koreth J. Optimal positioning of hematopoietic stem cell transplantation for older patients with myelodysplastic syndromes. Curr Opin Hematol 2013, 20:150-156.
32. Farag S.S., Maharry K., Zhang M.-J., et al. Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant 2011, 17:1796-1803.
33. Devine S.M., Ozwar K., Blum W., et al. Aphase II study of allogeneic transplantation for older patients with AML in first complete remission using a reduced intensity conditioning regimen: results from CALGB 100103/BMT CTN 0502. Blood 2012, 120(21):230.
34. Ho V.T., Kim H.T., Aldridge J., et al. Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression free survival after reduced intensity conditioning hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011, 17:1196-1204.